Premium
Alzamend Neuro Inc (ALZN)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipe... Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. Show more
Company to report on progress with clinical trials to be initiated in 2025 and expected milestones Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company...
Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer’s...
During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash...
Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and marketed lithium therapies At a low dose, AL001...
Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee Identified dose is unlikely to require...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar...
Fireside conversation to take place on October 17, 2024, at 1:30 PM ET Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0994 | -8.28333333333 | 1.2 | 1.2048 | 1.1 | 84766 | 1.14385505 | CS |
| 4 | -0.1094 | -9.04132231405 | 1.21 | 1.3 | 1.0927 | 89704 | 1.17461664 | CS |
| 12 | -0.3794 | -25.6351351351 | 1.48 | 1.5644 | 1.06 | 133392 | 1.2312974 | CS |
| 26 | -2.6594 | -70.7287234043 | 3.76 | 15.06 | 1.06 | 956422 | 4.7908487 | CS |
| 52 | -7.7994 | -87.6337078652 | 8.9 | 15.06 | 1.06 | 513644 | 4.941994 | CS |
| 156 | -216.3994 | -99.4939770115 | 217.5 | 239.25 | 1.06 | 450100 | 89.21902781 | CS |
| 260 | -4348.8994 | -99.9746988506 | 4350 | 5032.5 | 1.06 | 1103904 | 368.26814498 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 729,72M |
| NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,54M |
| RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 338,75M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,29M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 234,8M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
